Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis
Abstract Background and aims Limited data is available on the efficacy of direct acting anti-viral drugs on hepatitis C in drug users. The aim of this meta-analysis was to comprehensively analyze the efficacy and safety of LDV/SOF in drug users infected with the hepatitis C virus (HCV). Methods The...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-07-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-021-01625-w |
| _version_ | 1819128896440762368 |
|---|---|
| author | Xue Yang Yang Tang Di Xu Guang Zhang Peng Xu Houlin Tang Lin Pang |
| author_facet | Xue Yang Yang Tang Di Xu Guang Zhang Peng Xu Houlin Tang Lin Pang |
| author_sort | Xue Yang |
| collection | DOAJ |
| description | Abstract Background and aims Limited data is available on the efficacy of direct acting anti-viral drugs on hepatitis C in drug users. The aim of this meta-analysis was to comprehensively analyze the efficacy and safety of LDV/SOF in drug users infected with the hepatitis C virus (HCV). Methods The PubMed, Cochrane library, Embase and Web of Science databases were searched for articles published till April 2021 on HCV-positive drug users who were treated with ledipasvir/sofosbuvir (LDV/SOF). The primary endpoint was pooled sustained virological response at 12 weeks (SVR12) with 95% confidence interval (95% CI). Funnel plots and Egger’s test were used to assess the publication bias. Results A total of 12 studies and 711 subjects treated with LDV/SOF-based regimen for HCV were included, and the pooled SVR12 rate was 89.8% (95% CI 85.9–92.7). The pooled SVR12 rate of genotype 1 drug users was 92.4% (95% CI 88.6–95.0). Subgroup analysis showed that pooled SVR12 rates of patients treated with LDV/SOF and LDV/SOF ± RBV were 89.2% (95% CI 83.4–93.1), 90.4% (95% CI 83.6–94.5) respectively. In addition, the SVR12 rates were 88% (95% CI 70.7–95.7) for 8 weeks, 89.9% (95% CI 81.0–94.9) for 12 weeks and 82.2% (95% CI 24.9–98.5) for 24 weeks of treatment. Conclusion LDV/SOF is a safe and relatively effective treatment for hepatitis C in drug users. |
| first_indexed | 2024-12-22T08:35:06Z |
| format | Article |
| id | doaj.art-1d837f09573540f19ac3428a40b0427c |
| institution | Directory Open Access Journal |
| issn | 1743-422X |
| language | English |
| last_indexed | 2024-12-22T08:35:06Z |
| publishDate | 2021-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj.art-1d837f09573540f19ac3428a40b0427c2022-12-21T18:32:22ZengBMCVirology Journal1743-422X2021-07-0118111310.1186/s12985-021-01625-wEfficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysisXue Yang0Yang Tang1Di Xu2Guang Zhang3Peng Xu4Houlin Tang5Lin Pang6National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionNational Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and PreventionAbstract Background and aims Limited data is available on the efficacy of direct acting anti-viral drugs on hepatitis C in drug users. The aim of this meta-analysis was to comprehensively analyze the efficacy and safety of LDV/SOF in drug users infected with the hepatitis C virus (HCV). Methods The PubMed, Cochrane library, Embase and Web of Science databases were searched for articles published till April 2021 on HCV-positive drug users who were treated with ledipasvir/sofosbuvir (LDV/SOF). The primary endpoint was pooled sustained virological response at 12 weeks (SVR12) with 95% confidence interval (95% CI). Funnel plots and Egger’s test were used to assess the publication bias. Results A total of 12 studies and 711 subjects treated with LDV/SOF-based regimen for HCV were included, and the pooled SVR12 rate was 89.8% (95% CI 85.9–92.7). The pooled SVR12 rate of genotype 1 drug users was 92.4% (95% CI 88.6–95.0). Subgroup analysis showed that pooled SVR12 rates of patients treated with LDV/SOF and LDV/SOF ± RBV were 89.2% (95% CI 83.4–93.1), 90.4% (95% CI 83.6–94.5) respectively. In addition, the SVR12 rates were 88% (95% CI 70.7–95.7) for 8 weeks, 89.9% (95% CI 81.0–94.9) for 12 weeks and 82.2% (95% CI 24.9–98.5) for 24 weeks of treatment. Conclusion LDV/SOF is a safe and relatively effective treatment for hepatitis C in drug users.https://doi.org/10.1186/s12985-021-01625-wHepatitis CLedipasvir and sofosbuvirDrug usersSVR12Meta-analysis |
| spellingShingle | Xue Yang Yang Tang Di Xu Guang Zhang Peng Xu Houlin Tang Lin Pang Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis Virology Journal Hepatitis C Ledipasvir and sofosbuvir Drug users SVR12 Meta-analysis |
| title | Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis |
| title_full | Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis |
| title_short | Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis |
| title_sort | efficacy and safety of ledipasvir sofosbuvir for hepatitis c among drug users a systematic review and meta analysis |
| topic | Hepatitis C Ledipasvir and sofosbuvir Drug users SVR12 Meta-analysis |
| url | https://doi.org/10.1186/s12985-021-01625-w |
| work_keys_str_mv | AT xueyang efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis AT yangtang efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis AT dixu efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis AT guangzhang efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis AT pengxu efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis AT houlintang efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis AT linpang efficacyandsafetyofledipasvirsofosbuvirforhepatitiscamongdrugusersasystematicreviewandmetaanalysis |